Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for the fourth quarter of 2024. The company’s ... Read More
Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its shares leap by 23% following a robust ... Read More
Gamma Biosciences to sell Mirus Bio to Merck KGaA for $600m in key biotech deal
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio from Gamma Biosciences for $600 million in ... Read More
MilliporeSigma invests over €300m in new South Korean bioprocessing center
MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has earmarked an investment exceeding €300 million for the ... Read More
EMD Serono facility expansion in Massachusetts set to advance immuno-oncology research
German pharmaceutical giant Merck KGaA has announced a significant investment of $70 million to expand its EMD Serono research and development (R&D) facility located in ... Read More